Sovereign immunity: a venue-dependent protection
A recent University of Texas dispute perfectly illustrates the differing role sovereign immunity takes in proceedings at the Patent Trial and Appeal Board and district court, say Simon Roberts, Nitya Anand and Eric Wang of Hogan Lovells.
EPO’s new examination guidelines: what you need to know
The updated rules included important changes involving amino or nucleic acid sequences and antibodies, as Clare Roskell and Samantha Moodie of Mathys & Squire explain.
The uncertain future of antibody claims
Amgen v Sanofi continues the Federal Circuit’s trend of undermining certain antibody claims, explains Benjamin Pelletier of Haynes and Boone.
Got a patent, now where to validate?
For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.
Patent filing strategies for pharma startups
Patents are a key asset for pharmaceutical startups, but where are they choosing to file? Jian Siang Poh and Angus Fairbairn of Marks & Clerk report.
Texas Uni’s sovereign immunity fail went as expected
The result of the sovereign immunity bid mirrored previous cases but we did learn something about the opinions of Justices on the issue, says Gary Frischling of Milbank.
Second medical use: a regulatory perspective
Under close scrutiny by regulators, the rules around second medical use patents vary from country to country, explains Jackie Mulryne of Arnold & Porter.
The importance of Minerva Surgical v Hologic
A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.
What 2020 means for the life sciences
Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.
Pricing, patents and the PMPRB in Canada
Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.
